Theodore S Johnson, Tobey J MacDonald, Rafal Pacholczyk, Dolly Aguilera, Ahmad Al-Basheer, Manish Bajaj, Pratiti Bandopadhayay, Zuzana Berrong, Eric Bouffet, Robert C Castellino, Kathleen Dorris, Bree R Eaton, Natia Esiashvili, Jason R Fangusaro, Nicholas Foreman, Diana Fridlyand, Cole Giller, Ian M Heger, Chenbin Huang, Nadja Kadom, Eugene P Kennedy, Neevika Manoharan, William Martin, Colleen McDonough, Rebecca S Parker, Vijay Ramaswamy, Eric Ring, Amyn Rojiani, Ramses F Sadek, Sarthak Satpathy, Matthew Schniederjan, Amy Smith, Christopher Smith, Beena E Thomas, Rachel Vaizer, Kee Kiat Yeo, Manoj K Bhasin, David H Munn
BACKGROUND: Recurrent brain tumors are the leading cause of cancer death in children. Indoleamine 2,3-dioxygenase (IDO) is a targetable metabolic checkpoint that, in preclinical models, inhibits anti-tumor immunity following chemotherapy. METHODS: We conducted a phase I trial (NCT02502708) of the oral IDO-pathway inhibitor indoximod in children with recurrent brain tumors or newly diagnosed diffuse intrinsic pontine glioma (DIPG). Separate dose-finding arms were performed for indoximod in combination with oral temozolomide (200 mg/m2/day x 5 days in 28-day cycles), or with palliative conformal radiation...
February 2, 2024: Neuro-oncology